

Göttingen, December 16, 2020

Sartorius supports pharmaceutical training in Tanzania

- European medical aid organization action medeor receives 85,000 euros
- Sartorius initiative Christmas Donations Instead of Gifts

For Christmas, Sartorius is supporting an aid project to improve pharmaceutical training in Tanzania. The company's donation of 85,000 euros will go to action medeor, the European medical aid organization. This organization's project addresses young people who will provide healthcare in Tanzania after completing their education as non-academic pharmaceutical specialists in order to strengthen the country's health service infrastructure. This is intended to create better access to pharmaceutical training, especially in rural areas. In addition, action medeor is providing laboratory equipment to a public pharmaceutical school in the region of Mpanda.

"As a life science group, Sartorius is contributing toward the development and production of affordable medicines. In order for these to reach the people in Tanzania, well-trained pharmaceutical specialists are needed, and the country's health infrastructure as a whole must be strengthened. Vocational training is of great importance in this endeavor," said Petra Kirchhoff, Head of Sartorius Corporate Communications.

Within the scope of its Donations Instead of Gifts initiative, Sartorius is supporting an aid organization from the medical and pharmaceutical sectors for the seventh time, foregoing Christmas presents for customers and business partners. Moreover, Sartorius promotes further charitable initiatives at several company sites: Since 2018, for instance, the company has been donating to an SOS Children's Village in Bangalore, India, which gives orphaned children access to medicine and education.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann
Corporate Communications
+49 (0)551.308.4724
timo.lindemann@sartorius.com
www.sartorius.com

Follow Sartorius on [Twitter](#) @Sartorius_Group and on [LinkedIn](#).